Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-seq analysis of IMR32

ABSTRACT: ChIP-seq analysis of IMR32

PROVIDER: PRJNA862179 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR20634843.fastq.gz	Fastqsanger.gz
	SRR20634845.fastq.gz	Fastqsanger.gz
	SRR20634847.fastq.gz	Fastqsanger.gz
	SRR20634850.fastq.gz	Fastqsanger.gz
	SRR20634852.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

PML1: IMR32 vs empty vector IMR32

Project description:Transcriptional profiling of neuroblastoma cell line expressing the PML1 isoform. Two-condition experiment: PML1 IMR32 vs empty vector IMR32. Two biological replicates, dye-swapped.

2016-08-09 | E-GEOD-78086 | biostudies-arrayexpress

Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha

Project description:Estrogen Receptor alpha (ERα) is a key driver of most breast cancers, and it is the target of endocrine therapies used in the clinic to treat women with ERα positive (ER+) breast cancer. The two methods ChIP-seq (chromatin immunoprecipitation coupled with deep sequencing) and RIME (Rapid Immunoprecipitation of Endogenous Proteins) have greatly improved our understanding of ERα function during breast cancer progression and in response to anti-estrogens. A critical component of both ChIP-seq and RIME protocols is the antibody that is used to pull down the bait protein. To date, most of the ChIP-seq and RIME experiments for the study of ERα have been performed using the sc-543 antibody from Santa Cruz Biotechnology. However, this antibody has been discontinued, thereby severely impacting the study of ERα in normal physiology as well as diseases such as breast cancer and ovarian cancer. Here, we compare the sc-543 antibody with other commercially available antibodies, and we show that 06-935 (EMD Millipore) and ab3575 (Abcam) antibodies can successfully replace the sc-543 antibody for ChIP-seq and RIME experiments.

2019-03-21 | PXD012930 | Pride

Genome-wide analysis of DNA replication stress in the Human Neuroblastoma Cell Line IMR32 by TrAEL-seq

Project description:TrAEL-seq was used to assess the impact of Triapine (3AP), a RRM2 inhibitor, on replication fork accumulation and changes to the replication profile of IMR32 cells.

2022-08-02 | GSE186122 | GEO

Differentiation of IMR32 neuroblastoma is accompanied by a global change in the transcriptome

Project description:The aim of this study is to compare human transcriptomes based on NGS (RNA-seq). The transcriptome of neuroblastoma IMR32 was compared with the transcriptome of neuroblastoma IMR32, which was differentiated for 16 days in the presence of 2.5 mkM BrdU. Methods. Human mRNA profiles of 16-day differentiation of IMR32 neuroblastoma and non-differentiated IMR32 neuroblastoma were obtained by deep three-fold sequencing using Illumina NovaSeq. The mapping is read into the human genome (hg38) using the hisat program. On average, about 89-90% of all data received was unambiguously aligned in each library. The htseq-count utility has counted the number of reads that have been matched against known genes (ncbi - entrezID). The obtained values (cpm - countpermillion) for each gene for each library were combined into one matrix for further analysis. Results: Using an optimized data analysis workflow, we matched about 30 million sequence reads per sample to the human genome (hg38). Filtration, normalization by the method (TMM), variance estimation and differentially expressed genes estimation were performed in the edgeR module. Genes in which the cpm did not exceed 1 in any three libraries were considered low expressing.

2020-12-18 | GSE161759 | GEO

RNA-sequencing analysis to investigate genes regulated by HAND2 and MYCN in IMR32 cells

Project description:In this study we identified genes regulated by HAND2 or MYCN or both MYCN and HAND2 in IMR32 cells.

2023-03-29 | GSE183609 | GEO

ChIPseq of IMR32 cells treated with ISX or solvent control

Project description:IMR32 cells were treated with DMSO/ISX and Histone code and MycN binding was assessed via ChIPseq.

2023-01-17 | E-MTAB-12344 | biostudies-arrayexpress

RNA-sequencing analysis to identify genes regulated by MYCN, WDR5 and G9a in neuroblastoma cell line IMR32

Project description:In this study we identified genes regulated by MYCN, WDR5 and G9a in IMR32 cells

2023-10-19 | GSE208420 | GEO

ChIP-AP - An Integrated ChIP-Seq Analysis Pipeline

Project description:ChIP-AP - An Integrated ChIP-Seq Analysis Pipeline

| PRJNA723011 | ENA

ChIP-seq analysis of IMR32

Project description:In the present study, we found that EZH1 depletion in MYCN-amplified neuroblastoma cells resulted in significant cell death as well as xenograft inhibition. EZH1 depletion decreased the level of H3K27me1; the interaction and protein stabilization of MYCN and EZH1 appear to play roles in epigenetic transcriptional regulation. Transcriptome analysis of EZH1-depleted cells resulted in down-regulation of the cell cycle progression-related pathway. In particular, GSEA revealed down-regulation of reactome E2F-mediated regulation of DNA replication along with key genes of this process, TYMS, POLA2, and CCNA1. TYMS and POLA2 were transcriptionally activated by MYCN and EZH1-related epigenetic modification. Treatment with the EZH1/2 inhibitor UNC1999 also induced cell death, decreased H3K27 methylation, and reduced the levels of TYMS in NB cells. Previous reports indicated neuroblastoma cells are resistant to 5-fluorouracil (5-FU) and TYMS (encoding thymidylate synthetase) has been considered the primary site of action for folate analogues. Intriguingly, UNC1999 treatment significantly sensitized MYCN-amplified neuroblastoma cells to 5-FU treatment, suggesting that EZH inhibition may be an effective strategy for development of a new epigenetic treatment for neuroblastoma.

2022-07-28 | GSE209740 | GEO

Transcription profiling of IMR32 cells expressing 69-kDa or 82-kDa CHAT proteins

Project description:The goal of this study was to look at genes that were affected by 69-kDa and/or 82-kDa ChAT proteins in IMR32 cells Experiment Overall Design: The gene expression changes of IMR32 cells stably expressing either 69-kDa or 82-kDa ChAT proteins were anaylzed and compared to control IMR32 wild type cells. 3 biological replicates were anaylzed per condition (69-kDa ChAT expressing cells, 82-kDa ChAT expressing cells, or wild type IMR32 cells) for a total of 9 samples altogether.

2008-06-12 | E-GEOD-3506 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data